Aurora García-Rendón

Aurora García-Rendón

Auto-generated profile, based on publicly available information

Aurora García-Rendón

Department of Chemical Engineering and Metallurgy, University of Sonora, Hermosillo, Sonora, México

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2018 in Biotechnology and Genetic Engineering Reviews
Verified
Journal Article
Closed access
ATArmando Tejeda-Mansir
Armando Tejeda-Mansir
AGAurora García-Rendón
Aurora García-Rendón
PGPatricia Guerrero-German
Patricia Guerrero-German
Vaccination is the most effective and least expensive technique used for human diseases prevention and eradication. The need for more vaccine doses and the rapid establishment of facilities for the development of new vaccines are stimulating significate changes in the vaccine industry, which is gradually moving towards cell culture production. One approach is the third generation of vaccines, which are based on the use of plasmid DNA (pDNA) containing transgenes that encode an antigen capable of mimicking intracellular pathogenic infection and triggering both humoral and cellular immune responses. Plasmid DNA vaccination has distinct advantages over other vaccine technologies in terms of safety, ease of fabrication and stability. The effectiveness of pDNA vaccines against viruses, bacteria, parasites and cancer cells has been demonstrated in preclinical and clinical assays. Furthermore, currently there are a few veterinary pDNA vaccines in the market. The application of a simple formulation of naked pDNA as a vaccine is attractive, but a low transfection efficiency is often obtained. The use of nanoparticles to increase transfection efficiency is an approach that has been tested clinically. This review provides a summary of vaccine production, advances and major challenges associated with pDNA lipid and polymeric nanovaccines applications.

30 December 2014 in Biotechnology and Applied Biochemistry
Verified
Journal Article
Closed access
PDF file
RMRodolfo Munguía‐Soto
Rodolfo Munguía‐Soto
AGAurora García‐Rendón
Aurora García‐Rendón
AGAdriana Garibay‐Escobar
Adriana Garibay‐Escobar
PGPatricia Guerrero-German
Patricia Guerrero-German
ATArmando Tejeda-Mansir
Armando Tejeda-Mansir

22 April 2016 in Journal of Chemical Technology & Biotechnology
Verified
Journal Article
Closed access
PDF file
AGAurora García‐Rendón
Aurora García‐Rendón
RMRodolfo Munguía‐Soto
Rodolfo Munguía‐Soto
RMRosa M. Montesinos‐Cisneros
Rosa M. Montesinos‐Cisneros
RGRoberto Guzman
Roberto Guzman
ATArmando Tejeda-Mansir
Armando Tejeda-Mansir

1 January 2019 in Fuel
Verified
Journal Article
Closed access
LULuis A. Ureña-Búrquez
Luis A. Ureña-Búrquez
AGAurora García-Rendón
Aurora García-Rendón
CWCarmen sarai Rochin wong
Carmen sarai Rochin wong
ATArmando Tejeda-Mansir
Armando Tejeda-Mansir

1 January 2018
Verified
Book Chapter
Closed access
AGAurora García-Rendón
Aurora García-Rendón
AGAdriana Garibay-Escobar
Adriana Garibay-Escobar
RGRoberto Guzmán
Roberto Guzmán
ATArmando Tejeda-Mansir
Armando Tejeda-Mansir

1 January 2019 in Biotechnology & Biotechnological Equipment
Verified
Journal Article
Open access
AGAngelica García-Rendón
Angelica García-Rendón
RGRoberto Guzmán
Roberto Guzmán
ATArmando Tejeda-Mansir
Armando Tejeda-Mansir
The use of plasmid DNA (pDNA) for human vaccines is a novel approach against leishmaniasis, a neglected tropical disease with severe clinical manifestations. The development of feasible bioprocesses to obtain such vaccines is a public-health priority. The aim of this work was to investigate the substrate-source flexibility of an exponential-fed perfusion (EFP) system to produce the plasmid pVAX1-NH36 for use as a leishmaniasis vaccine. Batch and EFP cultures were conducted using Escherichia coli DH5α as a host and glucose or glycerol as a carbon source. The culture kinetics of the cell, substrate and plasmid concentrations were measured. Mathematical kinetics models were fitted to experimental data and used to describe the system comportment (r2 > 0.95). Plasmid productivities of 13.3 mg/(L h) using glucose and 19.4 mg/(L h) using glycerol were obtained. These levels represent a 1–3-fold increase in performance index compared with previously reported cultures using E. coli DH5α. The novel aspect of this work is the demonstration of the flexibility of EFP cultures for production of pDNA vaccines. Our data suggest that E. coli engineering to increase pDNA production using glucose can be circumvented with an EFP culture, reducing the host strain development costs. In addition, the greater productivity of EFP cultures entails a reduction in manufacturing costs.